Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
Pathogens (Basel, Switzerland)|August 6, 2021
Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study ProtocolMarie Pouquet, Dorine Decarreaux, Pol Prévot-Monsacré, et al.
BMC Medicine|November 30, 2021
Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Santé cohortMélanie Deschasaux-Tanguy, Bernard Srour, Laurent Bourhis, et al.
Scientific Reports|November 6, 2023
Association of SARS-CoV-2 infection with physical activity domains and typesJérémy Vanhelst, Bernard Srour, Laurent Bourhis, et al.
Blood|September 9, 2016
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infectionLuca Arcaini, Caroline Besson, Marco Frigeni, et al.
Gut|February 12, 2015
Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cureMirjam B Zeisel, Julie Lucifora, William S Mason, et al.
Blood|April 5, 2012
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas surveyBenjamin Terrier, Evguenia Krastinova, Isabelle Marie, et al.
Iscience|January 7, 2026
Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort studyGuillaume Martin-Blondel, Paul Burgat, Valentin Leducq, et al.
Journal of Crohn'S & Colitis|September 10, 2015
Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective StudyOdile Launay, Vered Abitbol, Anne Krivine, et al.
American Journal of Hematology|November 25, 2014
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C studyJean-Marie Michot, Danielle Canioni, Henda Driss, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Pageof 28